A study led by McMaster University has received a $4M investment from Canada’s COVID-19 Immunity Task Force to study the prevalence of COVID-19 antibodies within Canada’s 50+ population. The Canadian Longitudinal Study on Aging (CLSA) will undertake the COVID-19 Seroprevalence Study, which will determine how widespread SARS-CoV-2 infection is in the 50+ population through the use of blood tests and questionnaires. “As we begin a second wave of the pandemic,” said David Naylor, co-chair of the COVID-19 Immunity Task Force. “finding novel ways to further understand immunity in aging Canadians is increasingly important.” The study involves researchers from many academic and hospital research sites across the country, including McGill University and Dalhousie University.

Leave a comment